GMED
GLOBUS MEDICAL INC
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Best Medical Devices Stocks 2026 →
GLOBUS MEDICAL (GMED) Stock: Buy, Sell, or Hold?
$72.77
-2.63 (-3.48%)
▼
5d:
-10.65%
30d:
-4.65%
90d:
-15.29%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 05, 2026
0d
Protect GMED Gains
Updated Nov 12, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (52%)
Quality Score
41/100
Position
SLIGHTLY LOW
30-Day Fair Range
$74.69 – $81.46
Position: SLIGHTLY LOW
Forward P/E & Valuation
14.1x
CHEAP
vs 17.3x historical avg
Wall Street Target
$93.43
+23.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$70.40 / $88.10
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: GMED is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$121.21
Based on 5.6% avg growth
INTRINSIC VALUE TODAY
$75.26
3.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $72.77, which is considered slightly low relative to its 30-day fair value range of $74.69 to $81.46. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.1) compared to its historical average (17.3). Remarkably, the market is currently pricing in an annual earnings decline of 6.4% over the next few years. This pessimistic expectation contrasts with the company's recent 18.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GMED is in a downtrend. Immediate support is located at $70.39, while resistance sits at $88.10. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: GMED scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $93.43 (+23.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GMED is in a downtrend. Immediate support is located at $70.39, while resistance sits at $88.10. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: GMED scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $93.43 (+23.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$74.69 -
$81.46
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
Trading Range & Key Levels
30-Day Trading Range
$74.69 -
$81.46
Current vs Trading Range
SLIGHTLY LOW
Support Level
$70.40
Resistance Level
$88.10
Current Trend
Downtrend
Technical data as of
Nov 12, 2026
Protect Your Profits
Holding GMED? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (34/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 23.9% below Wall St target ($93.43)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
14.13
Wall Street Target
$93.43
(+23.9%)
Revenue Growth (YoY)
-0.7%
Earnings Growth (YoY)
18.2%
Profit Margin
17.8%
Valuation Discount vs History
-6.4% cheaper
PE vs Historical
14.1 vs 17.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.4%
(market-implied from PE analysis)
1-Year Target
$70.57
(-6%)
2-Year Target
$66.05
(-12%)
3-Year Target
$61.82
(-18%)
3-Yr Target (if PE normalizes)
(PE: 14→17)
$75.71
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 7.2%)
$130.47
(+73%)
Base:
(SPY PE: 14.1, Growth: 7.2%)
$92.80
(+23%)
Bear:
(PE: 12.0, Growth: 7.2%)
$78.88
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 18.53 | Current EPS (TTM): $4.06
Bull Case
$108.78
(+44%)
Analyst growth 31.5%, PE expands to 20.4
Base Case
$98.89
(+31%)
Market implied 31.5%, PE stable at 18.5
Bear Case
$51.16
(-32%)
Severe decline -20.0%, PE contracts to 15.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.1 to 17.3
Stabilization Target:
$92.33
(+22.5%)
PE Expansion Potential:
+22.5%
Share GMED Analysis
Share this live GMED analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (GMED)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Sep 20, 2026
Daily AI digest
AI Retail Discussion Summary:
Bullish sentiment on $GMED is driven by the strong product portfolio and focus on research and development at Ecolab Inc., as stated in a recent article.
Key Retail Themes:
Strong Product Portfolio
Innovation and R&D
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:51 PM ET
Data refreshes hourly during market hours. Next update: 3:51 PM
Data refreshes hourly during market hours. Next update: 3:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$119 | 48 HOLD |
|
BSX
Boston Scientific Corp |
BUY
31 analysts |
$50 | 51 HOLD |
|
EW
Edwards Lifesciences Corp |
STRONG BUY
30 analysts |
$112 | 33 SELL |
|
MDT
Medtronic PLC |
BUY
30 analysts |
$105 | 41 HOLD |
|
IRTC
iRhythm Technologies Inc |
STRONG BUY
16 analysts |
$166 | 54 HOLD |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive GMED Research Pages
